259 related articles for article (PubMed ID: 32908231)
21. Oncolytic Adenovirus rAd.DCN Inhibits Breast Tumor Growth and Lung Metastasis in an Immune-Competent Orthotopic Xenograft Model.
Zhao H; Wang H; Kong F; Xu W; Wang T; Xiao F; Wang L; Huang D; Seth P; Yang Y; Wang H
Hum Gene Ther; 2019 Feb; 30(2):197-210. PubMed ID: 30032645
[TBL] [Abstract][Full Text] [Related]
22. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
Liu Z; Yang Y; Zhang X; Wang H; Xu W; Wang H; Xiao F; Bai Z; Yao H; Ma X; Jin L; Wu C; Seth P; Zhang Z; Wang L
Hum Gene Ther; 2017 Aug; 28(8):667-680. PubMed ID: 28530155
[TBL] [Abstract][Full Text] [Related]
23. Magnetic Resonance Elastography reveals effects of anti-angiogenic glioblastoma treatment on tumor stiffness and captures progression in an orthotopic mouse model.
Schregel K; Nowicki MO; Palotai M; Nazari N; Zane R; Sinkus R; Lawler SE; Patz S
Cancer Imaging; 2020 May; 20(1):35. PubMed ID: 32398076
[TBL] [Abstract][Full Text] [Related]
24. Study of diffusion-weighted magnetic resonance imaging in the evaluation of the response to AAV2-VEGF-Trap neoadjuvant treatment in a triple-negative breast cancer animal model.
Li J; Zhu P; Wang L; Yang L; Zou L; Gao F
Cancer Med; 2019 Apr; 8(4):1594-1603. PubMed ID: 30900382
[TBL] [Abstract][Full Text] [Related]
25. Differentiation between Glioblastoma Multiforme and Primary Cerebral Lymphoma: Additional Benefits of Quantitative Diffusion-Weighted MR Imaging.
Ko CC; Tai MH; Li CF; Chen TY; Chen JH; Shu G; Kuo YT; Lee YC
PLoS One; 2016; 11(9):e0162565. PubMed ID: 27631626
[TBL] [Abstract][Full Text] [Related]
26. Predicting Glioblastoma Recurrence by Early Changes in the Apparent Diffusion Coefficient Value and Signal Intensity on FLAIR Images.
Chang PD; Chow DS; Yang PH; Filippi CG; Lignelli A
AJR Am J Roentgenol; 2017 Jan; 208(1):57-65. PubMed ID: 27726412
[TBL] [Abstract][Full Text] [Related]
27. Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study.
Huang SY; Lin HH; Yao M; Tang JL; Wu SJ; Hou HA; Chou WC; Chou SC; Hsu SC; Ko BS; Lu HY; Tsay W; Tien HF
PLoS One; 2015; 10(9):e0137552. PubMed ID: 26379028
[TBL] [Abstract][Full Text] [Related]
28. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB
BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012
[TBL] [Abstract][Full Text] [Related]
29. Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma.
Krishnan AP; Karunamuni R; Leyden KM; Seibert TM; Delfanti RL; Kuperman JM; Bartsch H; Elbe P; Srikant A; Dale AM; Kesari S; Piccioni DE; Hattangadi-Gluth JA; Farid N; McDonald CR; White NS
AJNR Am J Neuroradiol; 2017 May; 38(5):882-889. PubMed ID: 28279985
[TBL] [Abstract][Full Text] [Related]
30. Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma.
Ellingson BM; Patel K; Wang C; Raymond C; Brenner A; de Groot JF; Butowski NA; Zach L; Campian JL; Schlossman J; Rizvi S; Cohen YC; Lowenton-Spier N; Minei TR; Shmueli SF; Wen PY; Cloughesy TF
Neurooncol Adv; 2021; 3(1):vdab082. PubMed ID: 34377989
[TBL] [Abstract][Full Text] [Related]
31. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.
Pope WB; Kim HJ; Huo J; Alger J; Brown MS; Gjertson D; Sai V; Young JR; Tekchandani L; Cloughesy T; Mischel PS; Lai A; Nghiemphu P; Rahmanuddin S; Goldin J
Radiology; 2009 Jul; 252(1):182-9. PubMed ID: 19561256
[TBL] [Abstract][Full Text] [Related]
32. Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.
Nguyen HS; Milbach N; Hurrell SL; Cochran E; Connelly J; Bovi JA; Schultz CJ; Mueller WM; Rand SD; Schmainda KM; LaViolette PS
AJNR Am J Neuroradiol; 2016 Dec; 37(12):2201-2208. PubMed ID: 27492073
[TBL] [Abstract][Full Text] [Related]
33. Chondroitin sulfate content and decorin expression in glioblastoma are associated with proliferative activity of glioma cells and disease prognosis.
Tsidulko AY; Kazanskaya GM; Volkov AM; Suhovskih AV; Kiselev RS; Kobozev VV; Gaytan AS; Krivoshapkin AL; Aidagulova SV; Grigorieva EV
Cell Tissue Res; 2020 Jan; 379(1):147-155. PubMed ID: 31773303
[TBL] [Abstract][Full Text] [Related]
34. Multimodal imaging-defined subregions in newly diagnosed glioblastoma: impact on overall survival.
John F; Bosnyák E; Robinette NL; Amit-Yousif AJ; Barger GR; Shah KD; Michelhaugh SK; Klinger NV; Mittal S; Juhász C
Neuro Oncol; 2019 Feb; 21(2):264-273. PubMed ID: 30346623
[TBL] [Abstract][Full Text] [Related]
35. Reciprocal interplay between asporin and decorin: Implications in gastric cancer prognosis.
Basak D; Jamal Z; Ghosh A; Mondal PK; Dey Talukdar P; Ghosh S; Ghosh Roy B; Ghosh R; Halder A; Chowdhury A; Dhali GK; Chattopadhyay BK; Saha ML; Basu A; Roy S; Mukherjee C; Biswas NK; Chatterji U; Datta S
PLoS One; 2021; 16(8):e0255915. PubMed ID: 34379688
[TBL] [Abstract][Full Text] [Related]
36. Differentiating between Glioblastoma and Primary CNS Lymphoma Using Combined Whole-tumor Histogram Analysis of the Normalized Cerebral Blood Volume and the Apparent Diffusion Coefficient.
Bao S; Watanabe Y; Takahashi H; Tanaka H; Arisawa A; Matsuo C; Wu R; Fujimoto Y; Tomiyama N
Magn Reson Med Sci; 2019 Jan; 18(1):53-61. PubMed ID: 29848919
[TBL] [Abstract][Full Text] [Related]
37. Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T.
Doskaliyev A; Yamasaki F; Ohtaki M; Kajiwara Y; Takeshima Y; Watanabe Y; Takayasu T; Amatya VJ; Akiyama Y; Sugiyama K; Kurisu K
Eur J Radiol; 2012 Feb; 81(2):339-44. PubMed ID: 21129872
[TBL] [Abstract][Full Text] [Related]
38. Comparison between MRI-derived ADC maps and
Berro DH; Collet S; Constans JM; Barré L; Derlon JM; Emery E; Guillamo JS; Valable S
J Neuroradiol; 2019 Nov; 46(6):359-366. PubMed ID: 31229576
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-8/CXCR2 signaling regulates therapy-induced plasticity and enhances tumorigenicity in glioblastoma.
Hasan T; Caragher SP; Shireman JM; Park CH; Atashi F; Baisiwala S; Lee G; Guo D; Wang JY; Dey M; Wu M; Lesniak MS; Horbinski CM; James CD; Ahmed AU
Cell Death Dis; 2019 Mar; 10(4):292. PubMed ID: 30926789
[TBL] [Abstract][Full Text] [Related]
40. Diffusion restriction associated with bevacizumab treatment in recurrent glial tumors, evaluation of survival with ADC measurement analysis.
Savran B; Göç MF; Öztürk FU; Duran AO; Ünal Ö
Eur Rev Med Pharmacol Sci; 2023 May; 27(9):4153-4161. PubMed ID: 37203841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
